Eiger BioPharmaceuticals Stock Forecast, Price & News

Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks.

How has Eiger BioPharmaceuticals' stock price been impacted by COVID-19?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EIGR stock has decreased by 14.0% and is now trading at $5.86.
View which stocks have been most impacted by COVID-19.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Eiger BioPharmaceuticals.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.07. The biotechnology company earned $3.04 million during the quarter, compared to the consensus estimate of $2.54 million. During the same period last year, the company posted ($0.52) EPS.
View Eiger BioPharmaceuticals' earnings history.

What price target have analysts set for EIGR?

3 Wall Street analysts have issued 1 year price objectives for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $45.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $31.33 in the next twelve months. This suggests a possible upside of 434.7% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:

• David A. Cory, President, Chief Executive Officer & Director
• Sriram Ryali, Chief Financial Officer
• Ingrid C. Choong, Senior Vice President-Clinical Development
• Colin Hislop, Senior VP-Clinical & Development Operations
• Chris Dadas, Vice President-Medical Affairs

Who are some of Eiger BioPharmaceuticals' key competitors?

Some companies that are related to Eiger BioPharmaceuticals include Vaxart (VXRT), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX), Monte Rosa Therapeutics (GLUE), Omega Therapeutics (OMGA), Agenus (AGEN), Finch Therapeutics Group (FNCH), Sutro Biopharma (STRO), Cullinan Oncology (CGEM), bluebird bio (BLUE), Immatics (IMTX), Forma Therapeutics (FMTX), Mesoblast (MESO), Osiris Therapeutics (OSIR) and Adaptimmune Therapeutics (ADAP).
View all of EIGR's competitors.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (9.34%), BlackRock Inc. (7.28%), Geode Capital Management LLC (1.79%), Goldman Sachs Group Inc. (1.12%), Knott David M (0.92%) and Dimensional Fund Advisors LP (0.62%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Goldman Sachs Group Inc., California State Teachers Retirement System, New York State Common Retirement Fund, Two Sigma Investments LP, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Jane Street Group LLC, Sigma Planning Corp, Apis Capital Advisors LLC, Telemetry Investments L.L.C., and Dupont Capital Management Corp. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $5.86.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $199.12 million. The biotechnology company earns $-65.05 million in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 28 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at (650) 272-6138, via email at [email protected], or via fax at 650-618-1621.